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Humans develop polyclonal, serotype-specific neutralizing antibody responses after dengue virus (DENV) infection. Many
mouse antibodies that neutralize DENV bind to the lateral ridge or A strand epitopes on domain III of the viral envelope (EDIII)
protein. It has been assumed that these epitopes are also the main target of human neutralizing antibodies. Using recombinant
dengue serotype 2 viruses with altered EDIII epitopes, we demonstrate that EDIII epitopes are not the main target of human
neutralizing antibody.
Dengue viruses (DENV) are emerging, mosquito-borne flavi-viruses of humans (10). Some people infected with dengue
have asymptomatic or mild disease, while others develop classical
dengue fever (DF) or dengue hemorrhagic fever (DHF), which
can be fatal (12, 13). The DENV complex consists of 4 distinct but
related viruses designated as serotypes. Although infection with
one serotype stimulates an adaptive immune response that is
highly cross-reactive between serotypes, this response only pre-
vents reinfection with the homologous serotype (13). People ex-
periencing a second infection with a new serotype face a much
greater risk of developing DHF because preexisting, cross-reactive
immunity can exacerbate disease. A leading theory to explain the
association between preexisting immunity and severe disease is
antibody-dependent enhancement (ADE), which postulates that
cross-reactive, weakly neutralizing antibodies enhance the ability
of DENVs to infect Fc receptor-bearing cells (13) and the amount
of virions released from each infected cell (32). Antibodies also
play a key role in neutralizing DENVs and appear to provide long-
term protection from reinfection. Currently, several live attenu-
ated dengue vaccines are being tested in clinical trials. Despite the
advanced stage of live DENV vaccine development, we do not
know the properties of human antibodies responsible for potent
and long-term neutralization following natural infection.
The DENV envelope (E) protein that covers the surface of the
virion is the main target of neutralizing antibodies. Each folded E
protein molecule contains three distinct domains, designated
EDI, EDII, and EDIII (Fig. 1A) (21–23). Most mouse monoclonal
antibodies (MAbs) that strongly neutralize DENVs bind to
epitopes on the lateral ridge (LR) and A strand of EDIII (Fig. 1B)
(26, 28, 30, 31). The LR epitope is poorly conserved between
DENV serotypes, and antibodies that target this epitope only bind
and neutralize a single serotype (dengue type specific) (8, 31). The
A strand epitope is more conserved between serotypes, and anti-
bodies that bind to this epitope usually bind and neutralize more
than one serotype (dengue subcomplex) (31). Some antibodies
are sensitive to mutations in both the LR and A strand, indicating
that the footprints of these antibodies span both epitopes (8, 9,
19, 31).
As people exposed to DENV infections develop strong, type-
specific or subcomplex-neutralizing polyclonal antibody re-
sponses, it was plausible that human neutralizing antibodies
would also bind to epitopes on EDIII. However, our group and
other groups recently demonstrated that people exposed to DENV
infection develop low levels of EDIII binding, neutralizing anti-
body that accounted for 5 to 15% of the neutralizing activity in
human immune sera (20, 33). For those studies, we used recom-
binant EDIII expressed as a fusion protein to deplete EDIII bind-
ing antibodies from immune sera and then assessed the neutral-
ization titer of the depleted sera. One potential drawback to this
approach is that conformation differences between the recombi-
nant protein used for depletions and EDIII presented on the sur-
face of the virion may lead to incomplete depletion of antibodies.
To address this concern, we report here on the ability of human
immune sera to neutralize recombinant dengue serotype 2 viruses
(DENV2) that contain targeted mutations in the lateral ridge and
A strand EDIII epitopes.
The specific amino acid changes introduced to create the re-
combinant DENV2s and the location of these mutations on the
structure of EDIII are shown in Table 1 and Fig. 1C and D, respec-
tively. The recombinant DENV2 (rDENV2) cDNAs were made by
site-directed mutagenesis using the parental DENV2 clone, pD2/
IC-30P-NBX, which was originally developed using DENV2
strain 16681, as previously described (7, 15). The rDENV2 viruses
were derived by transfection of in vitro-transcribed RNA into the
C6/36 Aedes albopictus cell line at 28°C, and viral RNAs extracted
from resulting viruses were sequence analyzed to verify that the
genomes contained the engineered substitutions without other
unexpected mutations (15). Viruses were amplified in C6/36 cells
with minimal essential medium (MEM) (Gibco) supplemented
with 2% fetal bovine serum, penicillin (100 U/ml), and strepto-
mycin (100 g/ml) in the presence of 5% CO2. The FG loop mu-
tant viruses (D2IC20 and D2IC21) replicated well in insect cells
and mammalian cells, although replication in mammalian cells
was slower than that of the parental virus (7) The A strand mutant
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virus (D2IC24) also replicated in insect and mammalian cells,
although growth in both cell types was delayed compared to that
of the parental virus (data not shown). Therefore, the incubation
time for each mutant virus used in the neutralization assay was
adjusted to obtain a similar number of infected cells as with the
parental virus. These parental and recombinant viruses were used
in the neutralization assays as described by Wahala et al. with
minor modifications (33). Briefly, amounts of viruses predeter-
mined to give a 10-to-15% rate of infection and the monoclonal
antibodies or serum samples were incubated at 37°C for 1 h and
then added to a human monocytic cell line (U937) engineered to
express DC-SIGN, which is an attachment factor for DENVs. Af-
ter being incubated for 2 h at 28°C, cells were washed with fresh
medium and incubated for 48 to 60 h at 28°C. Cells were fixed,
permeabilized, and stained with Alexa Fluor 488-conjugated 2H2
dengue antibody. The percentages of infected cells at different
antibody concentrations were determined by flow cytometry,
and the 50% neutralization titer was determined using Graph-
Pad Prism version 4.00 for Windows (GraphPad Software, San
Diego, CA).
We used mouse MAbs that have previously been mapped to the
LR and A strand epitopes on EDIII to establish that these epitopes
were disrupted in the recombinant viruses used for this study. The
MAbs used and their contact residues in the EDIII protein are
summarized in Table 2. MAbs 1A1D2 and DV2-106 bind to the A
strand epitope centered on positions 303 to 305 (303-305), 307,
and 310 (3, 18, 30). Replacing lysine at positions 305, 307, and 310
with glutamic acid ablated neutralization by these two MAbs (Fig.
2), demonstrating that the A strand epitope was disrupted in this
virus. However, the FG loop mutant viruses were neutralized by
MAbs 1A1D2 and DV2-106, in agreement with previous epitope-
FIG 1 E protein structure of dengue virus type 2 and the location of EDIII mutations. (A) Individual subunits of E protein consist of three beta-barrel domains
designated domain I (EDI; red), II (EDII; yellow), and III (EDIII; blue), with the native protein forming a head-to-tail homodimer that lies flat on the surface of
the virus (21). (B) Enlarged view of EDIII. The lateral ridge (LR) epitope encompasses the BC loop, N linker region, and FG loop of the EDIII. The A strand
epitope is centered on the A strand. (C) The lateral ridge epitope was disrupted by deleting 4 amino acids on the FG loop (382–385) or replacing amino acids 382
to 384 (VEP replaced with RGD) on the FG loop to generate viruses DV2IC20 and DV2IC21, respectively. (D) The A strand epitope was disrupted by replacing
lysine at positions 305, 307, and 310 with glutamic acid (E).
TABLE 1 DENV2 EDIII mutant viruses used in the study
Virus Mutation EDIII epitopea Description
D2IC20 Deletion of amino
acids 382–385
LR (FG loop) FG loop mutant
D2IC21 VEP382-384RGD LR (FG loop) FG loop substituted
D2IC24 K305E, K307E, K310E A strand A strand mutant
D2IC30 None None Parental virus
a LR, lateral ridge.
TABLE 2 Properties of mouse MAbs used in current study
MAb MAb epitope residues E protein domain Reference(s)
4G2 104, 106–107, 231 EDII 4, 29
DV2-30 55, 71, 107, 244 EDII 30
DV2-106 303, 305, 307, 323, 389 EDIII A strand 30
1A1D2 304–310, 312, 323, 325, 364,
388–390
EDIII A strand 18, 31
9F16 301, 304–305, 327, 329,
383–384
EDIII lateral ridge 8, 9, 31
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mapping data, indicating that the FG loop was not a part of the A
strand epitope. MAb 9F16 has been mapped to residues 301, 304 –
305, 327, 329, 383, and 384 (8, 31), which form the lateral ridge
epitope on EDIII. All the mutant viruses used in this study but not
the wild-type parental virus escaped neutralization by MAb 9F16.
Our observation that both the mutations at the center of the lateral
ridge (383-385) and the mutations extending into the A strand
region led to escape from 9F16 was predicted from previous stud-
ies indicating that the 9F16 epitope includes both the LR and the A
strand. We conclude that the LR and the A strand epitopes were
severely compromised in the mutant recombinant DENV2s se-
lected for this study. The effect was specific for MAbs that have
been mapped to these epitopes, because non-EDIII antibodies
(MAb DV2-30 and 4G2) neutralized the mutant and parental vi-
ruses to similar extents (Fig. 2).
Previous studies have demonstrated that most DENV-
neutralizing antibodies in human sera were not directed to
epitopes on EDIII (20, 33). These studies were based on the use of
bacterially expressed recombinant EDIII antigen to deplete EDIII
antibodies in human sera. It is conceivable that the bacterially
produced protein may not deplete all EDIII A strand and LR an-
tibodies because of structural differences between recombinant
EDIII and native EDIII expressed on the surface of the virus. As an
alternate approach to assess whether the human neutralizing an-
tibody response was directed to EDIII LR and A strand epitopes,
we compared the ability of human dengue immune sera to neu-
tralize the recombinant viruses with mutations in the LR and A
strand epitopes. For these studies, we selected 4 dengue immune
sera from individuals exposed to primary DENV2 infections (Ta-
ble 3). All 4 sera neutralized DENV2 to high titers and showed
undetectable or lower titers to the other serotypes. Serially diluted
serum samples were tested to determine the neutralization titers
against each of the mutant viruses, as well as the parental virus. As
displayed in Fig. 3A, the 50% neutralization titers for each of the
serum samples against the mutant viruses were not significantly
different (P  0.05 at 95% confidence interval) from that of the
parental virus. These results demonstrate that LR and A strand
epitopes targeted by strongly neutralizing mouse antibodies are
not the main target of human neutralizing antibodies.
We performed a control experiment to determine whether a
polyclonal neutralizing antibody response directed against EDIII
was influenced by mutations in the LR and A strand epitopes. For
this experiment, we used serum from a rhesus macaque immu-
nized with an alphavirus vector expressing the ectodomain of
DENV2 E protein (residues 1 to 424), which induces EDIII neu-
tralizing antibodies (L. J. White, V. Yingsiwaphat, W. M. P. B.
Wahala, and A. M. de Silva, unpublished data). The serum was
tested for its ability to neutralize parental and EDIII LR- and A
strand mutant viruses. As depicted in Fig. 3B, the parental virus
FIG 2 Lateral ridge and A strand epitope mutant viruses escape neutralization by EDIII binding mouse MAbs. Neutralization assays were performed using
parental and mutant viruses and a panel of mouse MAbs that bind to different regions of E protein. The graph displays the mean percentages of neutralization
from two independent experiments for each MAb used at a concentration of 10 g/ml. Table 2 displays the binding sites of the MAbs used here. MAbs DV2-30
and 4G2 bind to epitopes on EDII. MAbs 1A1D2 and DV2-106 bind to the A strand of EDIII. MAb 9F16 binds to the lateral ridge epitope on EDIII. An epitope
was considered disrupted when mutations led to nearly complete neutralization escape from an antibody known to bind to the epitope.





serotypeDENV1 DENV2 DENV3 DENV4
01 20 271 20 41 DENV2
02 28 320 88 167 DENV2
03 20 650 22 24 DENV2
04 34 526 27 47 DENV2
a Fifty percent neutralization was calculated using a Vero81 cell-based immunofocus
assay according to the method of Kraus et al. (17). The reciprocal serum dilution that
gave a 50% neutralization of each DENV serotype is shown in the table.
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and the A strand mutant viruses were neutralized by the EDIII-
targeted vaccine serum. In contrast, the LR mutant viruses were
no longer neutralized by the EDIII vaccine serum. Further studies
are needed to understand why immunization with the ectodo-
main of E protein stimulated EDIII lateral ridge but not A strand
binding neutralizing antibodies, especially because some groups
are pursuing recombinant E protein antigens as dengue vaccine
candidates (2, 11, 14). We conclude that while EDIII-targeted im-
munizations can stimulate an LR-focused neutralizing antibody
response, most neutralizing antibodies in people exposed to
DENV2 infections are not directed against these epitopes.
Investigators have used the recombinant-antigen-based anti-
body depletion method to demonstrate that neutralizing antibod-
ies that develop after natural infection with dengue and West Nile
virus are not mainly directed to well-studied neutralizing anti-
body epitopes on EDIII (20, 27, 33). A significant concern with the
antibody depletion approach is that conformational differences
between the recombinant protein antigens and the native protein
on the virion may lead to incomplete depletion of EDIII antibod-
ies. Here, we used the alternate method of genetic alteration of key
epitopes on EDIII to test whether these epitopes were the main
target of human neutralizing antibodies. We used mutant DENVs
with multiple amino acid substitutions or deletions to drastically
alter the structure of these epitopes. Our results are consistent
with the conclusions of antibody depletion studies and indicate
that LR and A strand epitopes on EDIII are not the main target of
FIG 3 EDIII lateral ridge and A strand epitope mutant viruses remain sensitive to neutralization by dengue immune human sera. (A) Neutralization assays were
performed using parental and mutant viruses and 4 immune sera from people exposed to DENV2 infections. Serially diluted serum samples were used to calculate
the 50% neutralization titer against each virus. The mean 50% neutralization titers are displayed in the graph. The parental and mutant viruses were equally
sensitive to neutralization by the DENV 2 monotypic sera (P  0.05; confidence interval [CI], 95%). The properties of the sera used in the study are summarized
in Table 3. (B) Neutralization assays were performed using parental and mutant viruses and serum from a rhesus macaque immunized with an alphavirus vector
expressing dengue 2 E ectodomain (E residues 1 to 424). Macaque serum was diluted to 1:40, and the percentage of neutralization was calculated for each virus.
At a 1:40 dilution, lateral ridge mutant viruses (D2IC20 and D2IC21) were significantly more resistant to neutralization than the parental and A strand mutant
viruses (D2IC30 and D2IC24) (P  0.001; CI, 95%).
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human neutralizing antibodies. Studies with West Nile virus re-
porter virus particles (RVP) containing mutations in EDIII also
indicated that West Nile virus-infected people develop very low
levels of EDIII-focused neutralizing antibodies (24, 25, 27).
Several groups have recently reported on the properties of hu-
man MAbs generated from dengue virus- and West Nile virus-
immune subjects (1, 5, 6, 16). Although EDIII LR and A strand
binding human MAbs have been identified, most human antibod-
ies that strongly neutralize DENVs bind to other epitopes (1, 5, 6,
16). It is unclear whether the preponderance of EDIII-directed
neutralizing antibodies isolated from mice compared to the ratio
in humans is a result of inherent species differences or a result of
comparing mice immunized with dengue antigens or virions to
naturally infected humans. Studies are currently in progress to
compare antibody responses in mice and humans infected with
DENV (Katherine Williams, W. M. B. P. Wahala, Aravinda de
Silva, and Eva Harris, unpublished data). In summary, a growing
body of work now demonstrates that serotype-specific, strongly
neutralizing antibody responses that people develop after natural
DENV infections recognize epitopes that are distinct from the
well-studied LR and A strand epitopes engaged by strongly neu-
tralizing mouse antibodies.
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